SEC Form 4 · accession 0001209191-18-046800
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alex Sapir
Officer — President & CEO · Director
Period of report
Aug 14, 2018
Accepted (ET)
Aug 15, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 14, 2018 | P | 21,700 | $22.83 | A | 21,700 | I | By Trust |
| Common Stock | holding | — | — | — | 46,909 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.65 - 23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
- F2The reportable securities are owned directly by Alexander C. Sapir Revocable Trust (the "Trust"). The Reporting person is the trustee of the Trust.